MyFinsight
Home
Blog
About
Cash and cash
equivalents
$515,758
(-86.20%↓ Y/Y)
Prepaid expenses and
other assets
$71,048
(-22.79%↓ Y/Y)
Total current assets
$586,806
(-84.68%↓ Y/Y)
Operating lease
right-of-use assets
$50,384
(-35.18%↓ Y/Y)
Total assets
$637,190
(-83.69%↓ Y/Y)
Accumulated deficit
-$56,719,952
(-6.19%↓ Y/Y)
Total liabilities and
stockholders deficit
$637,190
(-83.69%↓ Y/Y)
Total stockholders
deficit
-$2,559,270
(-457.62%↓ Y/Y)
Additional paid-in capital
$54,143,303
(0.06%↑ Y/Y)
Common stock, 0.0001
par value...
$17,379
(0.71%↑ Y/Y)
Total liabilities
$3,196,460
(0.14%↑ Y/Y)
Deferred revenue
$3,000,000
(0.00%↑ Y/Y)
Total current
liabilities
$174,894
(24.96%↑ Y/Y)
Operating lease
obligations, less current...
$21,566
(-58.58%↓ Y/Y)
Accounts payable
$139,052
(30.87%↑ Y/Y)
Current portion of
operating lease...
$26,262
(1.06%↑ Y/Y)
Accrued expenses and
other liabilities
$9,580
(24.01%↑ Y/Y)
Back
Back
Balance Sheet
Inhibitor Therapeutics, Inc. (INTI)
Inhibitor Therapeutics, Inc. (INTI)
source: myfinsight.com